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The major change in medical decision making 
over the last 50 years has been the realisation 
that treatment decisions would be improved 
if doctors’ existing knowledge was supple -
mented by evidence generated systematically 
through health services research. This paper 
discusses this changing paradigm and explains 
the related activities of evidence-based 
medicine, comparative effectiveness research, 
and health technology assessment. The latter 
is particularly important for making decisions 
on the provision of healthcare at the 
population level. The key steps in undertaking 
health technology assessments are explained, 






hen we think of medical decision making, 
the image that comes to mind is that of the 
doctor discussing with the patient, diagnosing 
their health condition, and then using a lifetime 
of accumulated knowledge and experience to 
determine the most appropriate treatment. 
Indeed, this remains the case, but over the last 50 
years the paradigm of medical decision making 
has been changing, involving a greater role for 
published evidence and an expansion of the 
clinician’s role to include both individual-level 
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The objective of this paper is to examine the 
evolving role of medical decision making, and to 
explore its links with comparative effectiveness 
research and health technology assessment. A 
particular focus will be the types of literature that 
these activities have generated, with a view to 
assisting medical writers in their task of 
producing relevant text, thereby facilitating the 
publication of research papers relating to these 
topics. 
 
The changing paradigm of medical 
decision making 
When doctors use their accumulated knowledge 
and experience to make treatment decisions, they 
are mainly relying on a body of evidence that is 
based on what they learned during their training, 
and the results of their previous treatment 
decisions. However, this knowledge is not 
acquired systema tically, and in the middle of the 
last century it became clear that treatment 
decisions would be improved if doctors’ existing 
know ledge was supplemented by evidence 
generated systematically through clinical research.  
The cornerstone of clinical research is the 
randomised controlled trial (RCT), where in 
order to assess whether a new treatment does 
more good than harm, patients are randomly 
allocated to receive either a placebo or the 
current standard of care (the control group), or 
the new treatment (the experimental group). The 
purpose of randomisation is to minimise any 
biases in the assessment of comparative treat -
ment outcomes resulting from differences in the 
characteristics of the patients in the two treat -
ment groups. The main problem with studying 
the outcomes resulting from a new treatment in 
regular practice, without randomi sation, is the 
possibility of selection bias, whereby the new 
therapy is given to patients who are sicker than 
the average or are thought to be more likely 
benefit from it. 
 
Evidence-based medicine 
The notion that practising physicians should be 
considering evidence from the literature in their 
decision making has become known as evidence-
based medicine (EBM). There have been many 
thought leaders in this field, but one worth a 
special mention is Archie Cochrane, a Scottish 
physician and epidemiologist. While practising 
as an army medical officer in World War II, and 
then later dealing with the illnesses experienced 
by coal miners in South Wales, he realised that 
randomised controlled trials were the only 
reliable source of evidence on whether the 
treatments he was giving did more good than 
harm. 
The most important contribution of Coch -
rane’s career was the publication of a monograph 
called Effectiveness and efficiency: random 
reflections on health services in 1972.1 This book 
advocated the use of randomised controlled trials 
to make medicine more effective and efficient. 
Although Cochrane’s main concern was with 
(clinical) effectiveness, he also recognised that to 
maximise his contribution as a physician, he also 
needed to consider the resources he was using. 
His logic was that resources, such as the doctor’s 
own time, were limited, so that more time spent 
with one patient meant less time spent helping 
others. This raised the spectre of considering 
costs when making clinical decisions, which was 
controversial then and remains controversial 
today. (More on this later). 
Since Cochrane’s day the terminology has 
developed. Today we distinguish between the 
tthree E’s (Box 1). 
 
 
Box 1. Types of assessment of health 
care interventions 
 
Efficacy: Can the therapy work under ideal 
conditions? 
Effectiveness: Does therapy work in 
practice? 
Efficiency: Is the therapy worth the cost? 
 
 
The three E’s are each associated with their own 
set of literature. Efficacy studies are characterised 
by the clinical studies (normally randomised 
controlled trials) that are considered by 
regulatory health agencies such as the European 
Medicines Agency (EMA) or the Food and 
Drug Administration (FDA) in the US. In these 
studies, the new treatment (such as a drug, 
medical device, surgical procedure, or any 
“health technology”) is studied under ideal 
conditions. For example, the study may be 
conducted in a specialised clinical centre, the 
patients admitted to the study will not have any 
complicating co-existing health conditions other 
than the one for which the treatment is being 
given, patients and physicians will be ”blinded” 
to the therapy to which individual patients have 
been assigned, and care will be taken to ensure 
full adherence to the therapy. 
Efficacy studies are used to investigate 
whether the therapy does more good than harm 
as bodies like the EMA assess the trade-offs 
between the benefit the therapy offers and its 
risks (i.e., the possibility of adverse events). 
Recent examples are the judgements made by 
these agencies on the suitability of the vaccines 
for COVID-19. However, while efficacy is 
important to the health agencies, practising 
physicians and those funding healthcare are more 
interested in effectiveness studies because they 
want to know whether the therapy works in real 
life settings. There are several reasons why 
effectiveness might not reflect efficacy: the 
delivery of the treatment might require expertise 
or resources that are not widely available, the 
treatment might not work as well in patients with 
comorbidities (which were excluded from the 
efficacy studies), or the nature of the treatment 
(e.g. complicated dosing) may cause patients not 
to adhere closely to the treatment regimen. 
Therefore, effectiveness studies are conducted 
under conditions resembling regular practice. 
They are often randomised studies, termed 
”pragmatic” clinical trials, following the 
terminology developed by Schwartz and 
Lellouch.2  In fact, the distinction between 
efficacy and effectiveness is somewhat blurred, in 
that clinical trials may have differing levels of 
pragmatism (on a spectrum from efficacy to 
effectiveness) depending on the setting in which 
they are conducted, the breadth of the patient 
population enrolled, the level of patient 
monitoring, and so on. 
Many effectiveness studies are not 
randomised, however, because randomisation 
may not be possible when studying real life. 
Therefore, series of patients receiving different 
treatments may be compared in observational 
studies. A classic example would be the analysis 
of a large registry such as the National Joint 
Registry in the United Kingdom,3 which has 
enrolled thousands of patients receiving different 
types of joint replacements; another would be 
analysis of data from administrative claims 
databases in the US.4  The issue here is that since 
potential biases are not controlled by random -
isation, it is necessary to control for potential 
differences between patients through the data 
analysis. This can involve matching approaches, 
such as propensity scoring, or statistical 
approaches involving different types of 
multivariate regression.5 
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The success of all these analytic methods 
depends on the extent of information on the 
characteristics of patients that might inde -
pendently affect the effective ness 
of the therapy (e.g. age, previous 
treatment history, seriousness of 
disease, existence of other health 
conditions). Of course, it is only 
possible to account for patient 
differences that one is aware of, 
not those one is unaware of. 
Therefore, randomi sation is in 
theory superior because it can 
minimise all possibilities of bias, 
although some approaches, such 
as the use of instrumental 
variables in multi variate analyses, 
can mimic randomised studies.6 
For some health technologies, 
such as medical devices, random -
ised studies are rarely conducted 
because they may not be feasible 
or are not universally mandated by 
regulatory bodies such as the 
FDA. In these situations, it becomes necessary to 
rely on observational studies. 
Finally, efficiency studies assess whether a 
therapy is “worth it” by comparing the benefits 
with the costs. As mentioned earlier, the logic for 
including costs is that, under 
cond i tions of limited resources, 
the costs represent the benefits 
forgone to other patients. Some 
clinicians find this a difficult 
concept and struggle with it 
ethically. They are used to 
rationing care in emergency 
situations, such as triage on the 
battlefield or dealing with the 
allocation of intensive care beds 
during a pandemic, but it is not so 
easy to identify the resource 
constraints when working in a 
modern, well-resourced health 
care system. Also, it expects the 
doctor to consider not only the 
person currently being treated but 
a broader population of patients, 
most of whom are “not in the 
room”.7 However, as will be 
discussed later, doctors are increasingly becom -
ing involved in medical decision making at the 
population level as well as at the individual 
patient level. 
Efficiency studies are collectively called 
“economic evaluations” but generally go under 
the name of the particular form of economic 
evaluation, such as “cost-effectiveness analysis”, 
“cost-utility analysis”, or “cost-benefit analysis”.8 
All the methods follow the same general 
methodological approach but differ in the way 
the benefits are measured and valued. Cost-
effectiveness analysis (CEA) leaves the benefits 
in the clinical units of measurement, such as years 
of life gained, cases prevented, or disability 
avoided. Cost-utility analysis (CUA), also called 
CEA in the US literature, converts the clinical 
effects into a generic measure of health gain, the 
most well-known of which is the quality-adjusted 
life-year (QALY). Cost-benefit analysis (CBA) 
converts all the costs and benefits into monetary 
terms but is not very common in the health 
literature, owing to mixed feelings about placing 
a monetary value on improved health or life-years 
gained. 
The other major development following the 
Cochrane era was the realisation that although a 
single RCT is a reliable source of evidence about 
the efficacy or effectiveness of a treatment, it is 
ultimately specific to the precise circumstances 
in which it was conducted. It would be even more 
convincing if the same finding was reproduced in 
several similar clinical studies. Also, the precision 
by which a given relative clinical effect can be 
estimated depends on the sample size of the 
clinical trial. It follows that synthesising the 
results of several similarly conducted clinical 
trials would give more overall confidence in the 
result obtained and enable a more precise 
estimate of the relative clinical effect. 
This has been the motivation for conducting 
systematic reviews of clinical trials, or of the 
available clinical evidence more generally. The 
most important organisation that promotes the 
conduct and use of systematic reviews is 
appropriately named the Cochrane Collabora -
tion. This has developed into a major 
international movement with the mission “to 
promote evidence-informed health decision-
making by producing high-quality, relevant, 
accessible systematic reviews and other syn th -
esised research evidence”. The organi sation’s 
vision is “a world of improved health where 
decisions about health and healthcare are 
informed by high-quality, relevant, and up-to-















Can it work?                      Does it work?                                          Is it worth it? 
(Efficiency)                        (Effectiveness)                                      (Value)
Notes: 
n   EBM = evidence based medicine 
n   CER = comparative  effectiveness research 




Figure 1. Current confusion over the relationship between EBM, CER, and HTA. 
Reprinted with permission from Luce et al.14  
It follows that 
synthesising the 









enable a more 
precise estimate 
of the relative 
clinical effect. 
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Comparative effectiveness research 
Finally, “comparative effectiveness research” 
(CER) is a term that is now in common usage in 
the US. It refers to any type of effectiveness study, 
including pragmatic clinical trials, analysis of 
registries, and administrative databases. A 
committee of the Institute of Medicine in the US 
has defined CER as “the generation and synthesis 
of evidence that compares the benefits and harms 
of alternative methods to prevent, diagnose, treat, 
and monitor a clinical condition or to improve 
the delivery of care. The purpose of CER is to 
assist consumers, clinicians, purchasers, and 
policy makers to make informed decisions that 
will improve healthcare at both the individual 
and population levels”.10 
However, despite the intention to assist 
purchasers and policy makers, in most cases CER 
excludes consideration of costs. Indeed, the 
organisation established to fund these studies in 
the US, the Patient-Centred Outcomes Research 
Institute (PCORI), is explicitly barred from using 
measures such as the QALY under the terms of 
the Patient Protection and Affordable Care Act 
(also known as “Obamacare”) and does not 
generally fund economic evaluations.11  
 
Making better health care decisions: 
the rise of health technology 
assessment 
The discussion above indicates that both 
evidence-based medicine and comparative 
effectiveness research seek to improve medical 
and healthcare decision-making at the individual 
and population level. This is also the claim of 
health technology assessment (HTA), an 
approach that is increasingly popular in Europe 
and has been the subject of a major European 
Union (EU) joint action, the EUNetHTA 
project.12 HTA has been defined as “a 
multidisciplinary process that uses explicit 
methods to determine the value of a health 
technology at different points in its lifecycle. The 
purpose is to inform decision-making in order to 
promote an equitable, efficient, and high-quality 
health system”.13 Technology” in this case is 
defined very broadly and can mean a drug, a 
medical device, a surgical procedure, a prevention 
programme, or a system of organising healthcare. 
Luce et al.14 have explained the relationship 
between the three activities of EBM, CER, and 
HTA by categorising them according to two 
dimensions:  
i. the question being asked (can it work, does it 
work, is it worth it?) and  
ii. the main focus of the activity (evidence 
generation, evidence synthesis, decision 
making).  
 
Figure 1 illustrates that the three activities 
clearly overlap although they have slightly 
different emphasis in respect of the two 
dimensions. Figure 2 presents a more definitive 
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distinction between the three activities and 
illustrates the role of many of the analytical 
approaches described, along with the 
relationships between them.  
Health technology assessment is best viewed 
as the most over-arching activity of the three 
activities. It encompasses both clinical and 
economic assessments and although it is mostly 
relevant to population level decisions, it can be 
used at the individual patient level through a 
“shared decision making” approach in which the 
doctor discusses both the clinical and economic 
evidence with the patient. (See the paper by 
Finderup and Stacey in this issue.15) The explicit 
consideration of cost in shared decision making 
is particularly relevant in those settings, such as 
the US, where the patient may face a co-payment 
for their treatment. 
The key steps in the HTA process are outlined 
in Box 2.  
A full overview of HTA is given in the paper by 
Wendy Babidge in this issue,17 so only a brief 
description is given here, focusing on the studies 
that might be produced at each step. Topics for 
assessment are typically identified by several 
routes, e.g. recommendations for future research 
made by previous research studies, requests by 
government or other healthcare decision making 
bodies, or horizon scanning. Horizon scanning 
involves searching databases of ongoing clinical 
trials, the websites of technology manufacturers, 
and the general literature. The results of horizon 
scanning exercises are occasionally submitted for 
publication. 
Since it is not possible to assess every new 
technology given the resources available for 
HTA, priorities need to be set. The criteria most 
often used by HTA agencies are the anticipated 
clinical or economic impact of the new 
technology and the availability of evidence to 
conduct an assessment.18 
The specification of the decision problem is a 
very important step, which is often conducted 
through a scoping exercise. A common frame -
work used is called PICO. (Box 3). 
In the HTA step on “searching for evidence”, the 
most important feature is to have an effective 
search strategy to help identify the published and 
grey literature. The search strategy is normally 
presented in publications of systematic reviews, 
along with the outcome of the search. This is 
typically published in the form of a Preferred 
Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) diagram, showing the 
number of records/abstracts identified, the 
number and reasons for exclusions, and the final 
number of abstracts selected for full review.19 
The systematic review of the clinical evidence 
is one of the most important steps in the whole 
process and is almost always published, either as 
a free-standing paper or as part of the HTA 
report. The main objective is usually to produce 
a summary estimate of the relative clinical effect 
of the intervention as compared with the 
comparator, through a process called meta-
analysis. However, some studies only present a 
narrative review if it is considered that producing 
a summary estimate will be misleading or 
unhelpful. There are several important consid -
erations in systematic review such as checking for 
publication bias, assessing the quality of the 
included studies, and checking for heterogeneity 
in the studies. A good guide to undertaking 
systematic reviews has been produced by the 
Centre for Reviews and Dissemination at the 
University of York.20 
The final component of the assessment phase 
of the HTA process is economic evaluation. Not 
all HTAs contain an economic evaluation 
component, but this is more often the case now 
as issues of resource allocation and the efficient 
provision of healthcare are becoming increas ingly 
important. The economic evaluation may be 
published as part of the HTA report and as a free-
standing paper. Issues in the reporting of 
economic evaluations are explored in the paper 
by Husereau et al. in this issue.21 
The social, legal, and ethical implications need 
to be considered as adoption of some 
technologies may require changes in legislation 
or may infringe upon certain religious, social,  
or political principles. These issues may be 
discussed in the HTA report but do not often 
generate free-standing publications. 
Finally, the formulation of recommendations 
and implementation of policies suggested by the 
HTA are important steps as the whole purpose 
of HTA is to improve health care provision. 
Studies of the implementation of HTA findings 
and monitoring of the impact are sometimes 
undertaken and published as free-standing 
papers.22,23 
 
HTA in practice 
Health technology assessment has a history 
stretching back to the 1970s and is now practised 
in a wide range of countries. Experience with 
HTA in various countries is discussed in other 
papers in this issue.17,24 Given the broad 
application of HTA, it is possible to compare the 
approaches used and to specify principles of 
good practice. 
The practice of HTA varies between 
countries, both in the extent of its use and the 
methods used. For example, the UK and Canada 
are high users, but the US is a low user. The 
reasons for this are not entirely clear, but HTA 
seems to be more widely used in countries with 
a national health service or a national health 
insurance system. In countries like the US, with 
upwards of 1000 private health insurers, it is less 
clear that a single, centrally conduct ed HTA 
would be equally relevant in a wide range of 
diverse settings. 
l Identifying topics for assessment 
l Specifying the decision problem 
l Searching for evidence 
l Systematic review of the clinical 
evidence 
l Economic evaluation 
l Assessing social, legal, and ethical 
implications 
l Formulating recommendations and 
implementation of policies 
l Monitoring impact 
 
 
Box 2. Key steps in the HTA process
Patients/population: Which patients or 
populations are of interest? 
Intervention: What is the new intervention 
or technology to be studied? 
Comparison: What is/are the current 
alternative(s) to be compared with the new 
intervention (e.g. current standard of care) 
Outcome: What is/are the main 
outcome(s) of interest? 
 
*In some versions of the PICO framework, 
an “S” is added to PICO, representing study 
design.
Box 3. The PICO framework*
Adapted from Goodman16
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The difference in the 
methods used can be illustrated 
by the HTA of pharmaceuticals, 
which has become a formal part 
of the app roval process for 
reimbursement (i.e. payment by 
the healthcare system) in several 
countries. In some Northern 
European coun tries, such as the 
Netherlands, Sweden, and the 
UK, the pharma ceutical manu -
facturer has to produce an 
economic evaluation containing 
an estimation of the incremental 
cost per QALY gained from 
using the new drug compared 
with the existing standard of care. By contrast, 
HTA in France and Germany focuses on the 
“added clinical value” of the new drug, which is 
then used as a guide in the price negotiations 
between the healthcare payer and the manu -
facturer. Torbica et al.25,26 have 
explored whether these differences 
in approach can be attributed to 
differences in culture and values in 
the countries concerned or in their 
admini stra tive tradition and the 
organisation of healthcare. 
There have been several 
attempts to specify good practice 
principles for HTA. For example, 
Drummond et al.27 specified 15 key 
principles for the improved 
conduct of HTAs for resource 
allocation decisions in health care. 
These were grouped according to 
issues in  
i. the structure of HTA pro grammes (e.g. their 
indepen dence and remit),  
ii. the methods used (e.g. the range of costs and 
benefits considered),  
iii.   the processes followed (e.g. engagement of 
stakeholder groups), and  
iv.   the use in decision making (e.g. transparency 
in the link between HTA results and the 
decisions made).  
 
The same group of researchers then applied these 
principles to a range of existing HTA prog -
rammes worldwide and developed a set of 
questions for bench marking that those involved 
in HTA could use for self-evaluation.28,29  They 
concluded that the relevance of the various 
principles may vary according to the local setting 




The increasing role of evidence in medical 
decision making is clear, both at the individual 
patient level (primarily through EBM) and at the 
population level (primarily through CER and 
HTA). This increase in the use of evidence has 




in the extent of 
its use and the 
methods used. 
For example, the 
UK and Canada 
are high users, 

















Can it work? (Efficiency)                            Does it work? (Effectiveness)                                Is it worth it? (Value) 
                                                
Figure 2. Redefined relationships between evidence processes and analytical approaches. 
Solid lines indicate clear relationships, and dotted lines indicate disputed relationships. Diamonds represent decision processes, and 
circles and ovals represent all other evidence activities, except for the rectangles, which are reserved for EBM, HTA, and CER. 
Abbreviations: CED, coverage with evidence development; CER, comparative effectiveness research; EBM, evidence-based medicine; 
HTA, health technology assessment; PCT, pragmatic clinical trial;  RCT, randomised controlled trial; SRE, systematic review of evidence;  
SRT, systematic review of trials. 
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fuelled a large increase in the published literature, 
primarily in the areas of systematic reviews of 
clinical evidence and economic evaluation. This 
trend is likely to continue, given the shared 
interests of patients, healthcare policy makers, 
and the general public in improving the quality 
of healthcare decision making. In addition, we 
can expect to see a geographical spread of these 
approaches, which are already well-established in 
some middle-income countries. One priority 
area is to make the analyses conducted as useful 
as possible for the decision makers concerned, 
which is a particular challenge in multi-payer 
healthcare systems such as those in the US and 
in several middle-income countries in Latin 
America and Asia. 
 
Concluding remarks 
Given the increasing role of evidence in medical 
decision making, the interest in published studies 
in this field will be from a wide range of users of 
this evidence, including clinical practitioners, 
health policy makers, and patient organisations. 
Therefore, this literature is not exclusively aimed 
at researchers who are very familiar with the key 
concepts and terminology used. An important 
role of medical writing in this field is to help 
authors produce work that is accessible to this 
wide range of users with differing backgrounds 
and interests. 
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